Ghana becomes first river blindness-endemic country to approve moxidectin
Ghana FDA approves moxidectin for river blindness treatment, marking the first regulatory approval in an endemic country. The MOMENTUM pilot program will begin in Twifo Atti-Morkwa district in January 2025, aiming to accelerate parasite transmission elimination.
Bridging the gap to support groundbreaking RNA treatments
The BRIDGE program, coordinated by the Kirby Institute and UNSW Sydney, aims to advance Australian RNA research and bring new treatments to market. It supports RNA-based therapeutics development through partnerships, infrastructure, and a structured pipeline from proof-of-concept to clinical trials. The program collaborates with various institutions and includes a consumer representative for patient feedback.
© Copyright 2025. All Rights Reserved by MedPath